2. Signaling Pathways
  3. Cell Cycle/DNA Damage
    Cytoskeleton
  4. Mps1

Mps1

Monopolar spindle 1

Mps1

Related Products

PDF 0.04 MB

Monopolar spindle 1 (Mps1/TTK) is a serine/threonine kinase conserved from yeast to human. It has been shown to function as the key kinase that activates the spindle assembly checkpoint (SAC) to secure proper distribution of chromosomes to daughter cells.

MPS1, a dual specificity protein kinase, is also one of the main components of the SAC and ensures cells do not progress from metaphase to anaphase until the kinetochores are properly attached to the microtubules and under the appropriate tension at the metaphase plate. Cancer cells heavily rely on MPS1 to cope with aneuploidy resulting from aberrant numbers of chromosomes. The kinase has been found to be upregulated in a large number of tumor types. Mps1 is an attractive oncology target due to its high expression level in cancer cells as well as the correlation of its expression levels with histological grades of cancers.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-12859
    BAY1217389
    		Inhibitor 99.94%
    BAY 1217389 is a potent, and selective inhibitor of the monopolar spindle 1 (MPS1) kinase with an IC50 value less than 10 nM.
    BAY1217389
  • HY-101340A
    Luvixasertib hydrochloride
    		Inhibitor 99.63%
    CFI-402257 hydrochloride is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 hydrochloride has anti-cancer activity.
    Luvixasertib hydrochloride
  • HY-14710
    AZ3146
    		Inhibitor 99.42%
    AZ3146 is a reasonably potent Mps1 and TTK inhibitor, with IC50 of 35 nM for Mps1Cat.
    AZ3146
  • HY-12382
    NMS-P715
    		Inhibitor 99.30%
    NMS-P715 is a selective, ATP-competitive inhibitor of MPS1, with an IC50 of 182 nM.
    NMS-P715
  • HY-101340
    Luvixasertib
    		Inhibitor 99.77%
    CFI-402257 is a highly selective and orally bioavailable TTK/Mps1 inhibitor with an IC50 of 1.7 nM for TTK in vitro. CFI-402257 has anti-cancer activity.
    Luvixasertib
  • HY-171770
    dAurAB5
    		Inhibitor 99.03%
    dAurAB5 is a dual Aurora-A (DC50 = 8.8 nM) and Aurora-B (DC50 = 6.1 nM) PROTAC degrader. dAurAB5 induces degradation of Aurora-A and Aurora-B, reduces N-Myc levels, and decreases viability in IMR32 neuroblastoma cells. dAurAB5 downregulates the levels of AAK1, PTK2, GAK, and TTK. dAurAB5 can be used to study cancers such as neuroblastoma. (Pink: TTK ligand 2: HY-168542, Blue: Thalidomide-O-COOH: HY-103597, Black: 6-Aminocaproic acid: HY-B0236).
    dAurAB5
  • HY-116190
    CFI-401870
    		Inhibitor
    CFI-401870 is an orally active threonine tyrosine kinase (TKK (Mps1)) inhibitor with an IC50 of 3.1 nM. CFI-401870 exhibits IC50s against PLK4, KDR, AURKA and other kinases such as AURKB/INCENP were all greater than 1 μM.CFI-401870 inhibits the growth of various cancer cells, causing chromosome lag, an increase in aneuploidy and cell cycle arrest. CFI-401870 can be used for the study of cancers such as colon cancer.
    CFI-401870
  • HY-120032
    CFI-401980
    		Inhibitor
    CFI-401980 is a selective tyrosine threonine kinase MPS1 inhibitor with a Ki of 0.8 nM. CFI-401980 inhibits the proliferation of HCT116 cell lines. CFI-401980 can be studied in anti-cancer research.
    CFI-401980
  • HY-12660
    MPI-0479605
    		Inhibitor 99.54%
    MPI-0479605 is a potent and selective ATP-competitive inhibitor of Mps1, with an IC50 of 1.8 nM.
    MPI-0479605
  • HY-12401
    Mps1-IN-3
    		Inhibitor 99.73%
    Mps1-IN-3 is a potent and selective MPS1 kinase inhibitor, with an IC50 of 50 nM.
    Mps1-IN-3
  • HY-12858
    Empesertib
    		Inhibitor 99.22%
    Empesertib (BAY 1161909) is a potent Mps1 inhibitor, with an IC50 of < 1 nM.
    Empesertib
  • HY-100024
    NTRC 0066-0
    		Inhibitor 99.01%
    NTRC 0066-0 is a selective threonine tyrosine kinase (TTK) inhibitor (IC50=0.9 nM). NTRC 0066-0 can be used for the research of cancer.
    NTRC 0066-0
  • HY-112162
    BOS-172722
    		Inhibitor 98.65%
    BOS-172722 is an inhibitor of monopolar spindle 1 (MPS1) checkpoint with an IC50 of 11 nM and 63 nM for MPS1 (1 mM ATP) and P-MPS1, respectively. BOS-172722 also has potential for the study of various forms of breast cancer.
    BOS-172722
  • HY-168543
    PROTAC MPS1 degrader 2
    		Degrader 99.09%
    PROTAC MPS1 degrader 2 (Compound 15) is a potent degrader of monopolar spindle 1 (Mps1，TTK)，AURKA and AURKB，with DC50s of 42.0，2.1 and 154.0 nM，respectively. PROTAC MPS1 degrader 1 can be used for the research of acute myeloid leukemia. (Pink: ligand for target protein (HY-168545); Black: linker (HY-N0420); Blue: ligand for E3 ligase (HY-10984).
    PROTAC MPS1 degrader 2
  • HY-110115
    TC-Mps1-12
    		Inhibitor 99.76%
    TC-Mps1-12 is a potent and selective monopolar spindle 1 (Mps1) inhibitor, with an IC50 of 6.4 nM.
    TC-Mps1-12
  • HY-13994
    Mps1-IN-2
    		Inhibitor 98.08%
    Mps1-IN-2 is a potent, selective and ATP-competitive dual Mps1/Plk1 inhibitor, with an IC50 and a Kd of 145 nM and 12 nM for Mps1 and a Kd of 61 nM for Plk1.
    Mps1-IN-2
  • HY-13298
    Mps1-IN-1
    		Inhibitor 99.77%
    Mps1-IN-1 is a potent, selective and ATP-competitive Mps1 kinase inhibitor, with an IC50 and a Kd of 367 nM and 27 nM.
    Mps1-IN-1
  • HY-117291A
    XMD-17-51 TFA
    		99.46%
    XMD-17-51 TFA is a pyrimido-diazepinone compound that is able to modulate protein kinases.
    XMD-17-51 TFA
  • HY-12603
    CCT251455
    		Inhibitor 99.10%
    CCT251455 is a potent and selective mitotic kinase monopolar spindle 1 (MPS1) inhibitor with an IC50 of 3 nM.
    CCT251455
  • HY-110242
    Mps-BAY2a
    		Inhibitor 99.30%
    Mps-BAY2a is a monopolar spindle 1 (MPS1) inhibitor with an IC50 of 1 nM against human MPS1. Mps-BAY2a induces mitotic aberrations and apoptosis in cancer cells.
    Mps-BAY2a
Cat. No. Product Name / Synonyms Application Reactivity